Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Outcomes of patients who are BCMA-exposed versus BCMA-naïve in penta-R/R myeloma

Aytaj Mammadzadeh • 20 Dec 2022
ASH 2022
Multiple Myeloma Antibodies CAR-T Daratumumab Isatuximab

Aytaj Mammadzadeh, MD, US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS, discusses a retrospective analysis which evaluated the survival outcomes of patients with penta-relapsed/refractory multiple myeloma (penta-RRMM) receiving BCMA-directed therapy versus BCMA-naïve patients. Results demonstrated a significant survival benefit in those receiving BCMA-directed therapy, and Dr Mammadzadeh also comments on the need for novel treatment strategies for these patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals